ENLIVEN THERAPEUTICS, INC. Other Non-Current Assets
ENLIVEN THERAPEUTICS, INC. (ELVN) had Other Non-Current Assets of $1.24 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OtherAssetsNoncurrent · last filed 2026-08-05
- 2026-06-30: Other Assets, Noncurrent $1.24M.
- 2026-03-31: Other Assets, Noncurrent $1.19M.
- 2025-12-31: Other Assets, Noncurrent $656.00K.
- 2025-09-30: Other Assets, Noncurrent $7.10M.
| Period end | Other Assets, Noncurrent | Other Assets, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $1.24M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $1.19M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $656.00K 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $7.10M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $7.24M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $7.20M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $7.17M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $7.24M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $7.56M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $4.09M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $4.09M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $3.61M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $3.41M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $3.40M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 | $2.32M 10-K · filed 2023-02-10 |
| 2022-06-30 | $175.00K 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $175.00K 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $175.00K 10-K · filed 2023-02-10 | |
| 2021-09-30 | $175.00K 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $175.00K 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $308.00K 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $88.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | $88.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $324.00K 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $88.00K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $2.23M 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |